Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update

Virax Biolabs Group Limited (NASDAQ:VRAXGet Free Report) was the target of a large increase in short interest in January. As of January 31st, there was short interest totalling 100,500 shares, an increase of 233.9% from the January 15th total of 30,100 shares. Approximately 8.5% of the shares of the stock are sold short. Based on an average daily volume of 124,700 shares, the days-to-cover ratio is presently 0.8 days.

Virax Biolabs Group Stock Up 1.8 %

VRAX stock traded up $0.02 during mid-day trading on Monday, hitting $0.86. The company had a trading volume of 75,922 shares, compared to its average volume of 148,687. Virax Biolabs Group has a 12-month low of $0.74 and a 12-month high of $16.00. The company has a 50-day moving average price of $1.26 and a 200 day moving average price of $2.48.

Institutional Trading of Virax Biolabs Group

Hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new stake in Virax Biolabs Group in the 4th quarter worth $35,000. UBS Group AG purchased a new stake in shares of Virax Biolabs Group during the 3rd quarter valued at about $38,000. Legal & General Group Plc purchased a new stake in shares of Virax Biolabs Group during the 4th quarter valued at about $73,000. Finally, Armistice Capital LLC purchased a new stake in shares of Virax Biolabs Group during the 1st quarter valued at about $1,043,000. Hedge funds and other institutional investors own 0.37% of the company’s stock.

About Virax Biolabs Group

(Get Free Report)

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.

Featured Articles

Receive News & Ratings for Virax Biolabs Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virax Biolabs Group and related companies with's FREE daily email newsletter.